Proteomic identification of matrix metalloproteinase substrates in the human vasculature

Circulation: Cardiovascular Genetics

Volumn 6, Issue 1, 2013, Pages 106-117

  Stegemann, Christin ^a,b   Didangelos, Athanasios ^a,b   Barallobre Barreiro, Javier ^a,b   Langley, Sarah R ^a,b   Mandal, Kaushik ^c   Jahangiri, Marjan ^d   Mayr, Manuel ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Arteries; Atherosclerosis; Metalloproteinases; MMP; Proteomics

Indexed keywords

GELATINASE B; MATRIX METALLOPROTEINASE 14; SCLEROPROTEIN; STROMELYSIN; TENASCIN; TRANSCRIPTION FACTOR RUNX2;

ADULT; BASEMENT MEMBRANE; CASE REPORT; CONTROLLED STUDY; ELASTIC FIBER; ENZYME ANALYSIS; ENZYME DEGRADATION; ENZYME ISOLATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEOMICS; REVIEW; VASCULARIZATION;

ADULT; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROTEOMICS; RADIAL ARTERY; YOUNG ADULT;

EID: 84878050086     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.112.964452     Document Type: Review

References (47)

1. Newby AC. Matrix metalloproteinase inhibition therapy for vascular diseases. Vascul Pharmacol. 2012;56:232-244.
2. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;274:21491-21494.
3. Ray BK, Shakya A, Turk JR, Apte SS, Ray A. Induction of the MMP-14 gene in macrophages of the atherosclerotic plaque: role of SAF-1 in the induction process. Circ Res. 2004;95:1082-1090.
4. Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and nonmatrix substrates. Cardiovasc Res. 2006;69:614-624.
5. Sluijter JP, Pulskens WP, Schoneveld AH, Velema E, Strijder CF, Moll F, et al. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke. 2006;37:235-239.
6. Yin X, Cuello F, Mayr U, Hao Z, Hornshaw M, Ehler E, et al. Proteomics analysis of the cardiac myofilament subproteome reveals dynamic alterations in phosphatase subunit distribution. Mol Cell Proteomics. 2010;9:497-509.
7. Barallobre-Barreiro J, Didangelos A, Schoendube FA, Drozdov I, Yin X, Fernández-Caggiano M, et al. Proteomics analysis of cardiac extracellular matrix remodeling in a porcine model of ischemia/reperfusion injury. Circulation. 2012;125:789-802.
8. Choi H, Fermin D, Nesvizhskii AI. Significance analysis of spectral count data in label-free shotgun proteomics. Mol Cell Proteomics. 2008;7:2373-2385.
9. d'Ortho MP, Will H, Atkinson S, Butler G, Messent A, Gavrilovic J, et al. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem. 1997;250:751-757.
10. Murphy G, Reynolds JJ, Bretz U, Baggiolini M. Partial purification of collagenase and gelatinase from human polymorphonuclear leucocytes: analysis of their actions on soluble and insoluble collagens. Biochem J. 1982;203:209-221.
11. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem. 1996;271:10079-10086.
12. Myint E, Brown DJ, Ljubimov AV, Kyaw M, Kenney MC. Cleavage of human corneal type VI collagen alpha 3 chain by matrix metalloproteinase- 2. Cornea. 1996;15:490-496.
13. Prudova A, auf dem Keller U, Butler GS, Overall CM. Multiplex N-terminome analysis of MMP-2 and MMP-9 substrate degradomes by iTRAQTAILS quantitative proteomics. Mol Cell Proteomics. 2010;9:894-911.
14. Butler GS, Dean RA, Tam EM, Overall CM. Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: dynamics of membrane type 1 matrix metalloproteinase-mediated membrane protein shedding. Mol Cell Biol. 2008;28:4896-4914.
15. Fukai F, Ohtaki M, Fujii N, Yajima H, Ishii T, Nishizawa Y, et al. Release of biological activities from quiescent fibronectin by a conformational change and limited proteolysis by matrix metalloproteinases. Biochemistry. 1995;34:11453-11459.
16. Imai K, Kusakabe M, Sakakura T, Nakanishi I, Okada Y. Susceptibility of tenascin to degradation by matrix metalloproteinases and serine proteinases. FEBS Lett. 1994;352:216-218.
17. Siri A, Knäuper V, Veirana N, Caocci F, Murphy G, Zardi L. Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem. 1995;270:8650-8654.
18. Zhen EY, Brittain IJ, Laska DA, Mitchell PG, Sumer EU, Karsdal MA, et al. Characterization of metalloprotease cleavage products of human articular cartilage. Arthritis Rheum. 2008;58:2420-2431.
19. Auf dem Keller U, Prudova A, Gioia M, Butler GS, Overall CM. A statistics- based platform for quantitative N-terminome analysis and identification of protease cleavage products. Mol Cell Proteomics. 2010;9:912-927.
20. Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaissé J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett. 2000;486:247-251.
21. Didangelos A, Yin X, Mandal K, Baumert M, Jahangiri M, Mayr M. Proteomics characterization of extracellular space components in the human aorta. Mol Cell Proteomics. 2010;9:2048-2062.
22. Didangelos A, Yin X, Mandal K, Saje A, Smith A, Xu Q, et al. Extracellular matrix composition and remodeling in human abdominal aortic aneurysms: a proteomics approach. Mol Cell Proteomics. 2011;10:M111.008128.
23. Klingler D, Hardt M. Targeting proteases in cardiovascular diseases by mass spectrometry-based proteomics. Circ Cardiovasc Genet. 2012;5:265.
24. Didangelos A, Stegemann C, Mayr M. The -omics era: proteomics and lipidomics in vascular research. Atherosclerosis. 2012;221:12-17.
25. López-Otín C, Overall CM. Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol. 2002;3:509-519.
26. Tam EM, Morrison CJ, Wu YI, Stack MS, Overall CM. Membrane protease proteomics: isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc Natl Acad Sci USA. 2004;101:6917-6922.
27. Vaisar T, Kassim SY, Gomez IG, Green PS, Hargarten S, Gough PJ, et al. MMP-9 sheds the beta2 integrin subunit (CD18) from macrophages. Mol Cell Proteomics. 2009;8:1044-1060.
28. Greenlee KJ, Corry DB, Engler DA, Matsunami RK, Tessier P, Cook RG, et al. Proteomic identification of in vivo substrates for matrix metalloproteinases 2 and 9 reveals a mechanism for resolution of inflammation. J Immunol. 2006;177:7312-7321.
29. Schilling O, Overall CM. Proteome-derived, database-searchable peptide libraries for identifying protease cleavage sites. Nat Biotechnol. 2008;26:685-694.
30. Schilling O, Huesgen PF, Barré O, Auf dem Keller U, Overall CM. Characterization of the prime and non-prime active site specificities of proteases by proteome-derived peptide libraries and tandem mass spectrometry. Nat Protoc. 2011;6:111-120.
31. Dix MM, Simon GM, Cravatt BF. Global mapping of the topography and magnitude of proteolytic events in apoptosis. Cell. 2008;134:679-691.
32. Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, et al. Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003;21:566-569.
33. Kleifeld O, Doucet A, Auf dem Keller U, Prudova A, Schilling O, Kainthan RK, et al. Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products. Nat Biotechnol. 2010;28:281-288.
34. Didangelos A, Mayr U, Monaco C, Mayr M. Novel role of ADAMTS-5 protein in proteoglycan turnover and lipoprotein retention in atherosclerosis. J Biol Chem. 2012;287:19341-19345.
35. Stegemann C, Drozdov I, Shalhoub J, Humphries J, Ladroue C, Didangelos A, et al. Comparative lipidomics profiling of human atherosclerotic plaques. Circ Cardiovasc Genet. 2011;4:232-242.
36. Kielty CM, Sherratt MJ, Shuttleworth CA. Elastic fibres. J Cell Sci. 2002;115(pt 14):2817-2828.
37. Van Herck JL, De Meyer GR, Martinet W, Van Hove CE, Foubert K, Theunis MH, et al. Impaired fibrillin-1 function promotes features of plaque instability in apolipoprotein E-deficient mice. Circulation. 2009;120:2478-2487.
38. Mao JR, Taylor G, Dean WB, Wagner DR, Afzal V, Lotz JC, et al. Tenascin- X deficiency mimics Ehlers-Danlos syndrome in mice through alteration of collagen deposition. Nat Genet. 2002;30:421-425.
39. Huang W, Chiquet-Ehrismann R, Moyano JV, Garcia-Pardo A, Orend G. Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res. 2001;61:8586-8594.
40. Wallner K, Li C, Shah PK, Fishbein MC, Forrester JS, Kaul S, et al. Tenascin- C is expressed in macrophage-rich human coronary atherosclerotic plaque. Circulation. 1999;99:1284-1289.
41. Maruhashi T, Kii I, Saito M, Kudo A. Interaction between periostin and BMP-1 promotes proteolytic activation of lysyl oxidase. J Biol Chem. 2010;285:13294-13303.
42. Lindner V, Wang Q, Conley BA, Friesel RE, Vary CP. Vascular injury induces expression of periostin: implications for vascular cell differentiation and migration. Arterioscler Thromb Vasc Biol. 2005;25: 77-83.
43. Talusan P, Bedri S, Yang S, Kattapuram T, Silva N, Roughley PJ, et al. Analysis of intimal proteoglycans in atherosclerosis-prone and atherosclerosis- resistant human arteries by mass spectrometry. Mol Cell Proteomics. 2005;4:1350-1357.
44. Marneros AG, Olsen BR. The role of collagen-derived proteolytic fragments in angiogenesis. Matrix Biol. 2001;20:337-345.
45. Schenk S, Quaranta V. Tales from the crypt[ic] sites of the extracellular matrix. Trends Cell Biol. 2003;13:366-375.
46. Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem. 1992;267:3581-3584.
47. Arrell DK, Terzic A. Systems proteomics for translational network medicine. Circ Cardiovasc Genet. 2012;5:478.